LPCN Stock UPDATES Lipocine Inc (LPCN) 4.88 10/22/2014 00:25
Post# of 273230
Lipocine Announces Positive Top-Line Results in Phase 2a Study of LPCN 1111
GlobeNewswire - Mon Oct 13, 6:09AM CDT
Candidate For Once Daily Dosing
LPCN: 4.88 (+0.08)
IPOs and Transactions Week in Review: September 29 - October 3
PR Newswire - Mon Oct 06, 1:25PM CDT
Vintage, the capital markets division of PR Newswire, has released its weekly IPO and Transaction summary.
RCAP: 19.97 (+1.12), CPTA: 18.19 (+0.27), PTN: 0.69 (-0.01), LPCN: 4.88 (+0.08), XGTI: 1.69 (+0.02), ENRJ: 6.00 (+0.01), SINO: 2.04 (+0.31)
SOXX, XONE, LPCN, Added To Naked Short Lists Today
M2 - Mon Oct 06, 9:30AM CDT
BUYINS.NET, www.buyins.net , announced today that these select companies have been Added To the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. iShares PHLX SOX Semiconductor Sector Index Fund (NASDAQ:SOXX), (NASDAQ:XONE), (NASDAQ:LPCN). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
XONE: 21.56 (-0.41), LPCN: 4.88 (+0.08), SOXX: 82.34 (+2.93)
Nasdaq stocks posting largest percentage decreases
AP - Thu Oct 02, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
RESN: 6.25 (-0.14), ENPH: 13.80 (+1.57), EGLT: 5.73 (+0.86), GLBZ: 12.57 (+0.02), MSON: 10.19 (+0.42), ADHD: 5.12 (-0.20), LAKE: 14.94 (+0.01), LPCN: 4.88 (+0.08), GTLS: 47.99 (+2.02), CREE: 33.15 (+0.25)
Nasdaq stocks posting largest volume increases
AP - Thu Sep 25, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
OBCI: 4.41 (+0.21), LYTS: 6.47 (-0.03), ALCS: 0.30 (+0.01), ENVI: 1.62 (unch), JACQ: 11.00 (unch), LPCN: 4.88 (+0.08), FNJN: 2.42 (+0.07), RITT: 1.21 (+0.06), LAND: 12.00 (+0.32), ACOR: 32.58 (+0.20), FORD: 1.23 (-0.01)
Why Lipocine (LPCN) Stock Is Surging in Morning Trading Today
at The Street - Wed Sep 24, 8:50AM CDT
Shares of Lipocine (LPCN) soared in morning trading Wednesday after the pharmaceutical company announced positive results from its Phase 3 trial of its oral treatment LPCN 1021 for low testosterone.
LPCN: 4.88 (+0.08)
Lipocine Announces Positive Top-Line Results in Its Phase 3 Study of LPCN 1021 for Oral Testosterone Replacement Therapy
GlobeNewswire - Wed Sep 24, 7:30AM CDT
-- Met primary efficacy endpoint by successfully restoring testosterone levels to the normal range in 88% of the subjects
LPCN: 4.88 (+0.08)
Lipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Phase 3 Study of LPCN 1021
GlobeNewswire - Tue Sep 23, 3:00PM CDT
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that the Company will host a conference call and webcast tomorrow, September 24, 2014 at 8:45 a.m. Eastern time to discuss top-line results from its Study of Oral Androgen Replacement ("SOAR" pivotal Phase 3 clinical study (http://clinicaltrials.gov/show/NCT02081300). The Company plans to issue a press release detailing top-line results tomorrow prior to the conference call.
LPCN: 4.88 (+0.08)
Lipocine Announces First Patient Dosed in Phase 1 Study in Pregnant Women of LPCN 1107, Potentially the First Oral Product for the Prevention of Preterm Birth
GlobeNewswire - Mon Sep 08, 3:16PM CDT
Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the first patient was dosed in a Phase 1 study in pregnant women of LPCN 1107, the company's oral hydroxyprogesterone caproate (HPC) product candidate. The primary objectives of the study will be to determine safety, tolerability and pharmacokinetics of oral administration of LPCN 1107 in pregnant subjects.
LPCN: 4.88 (+0.08)